17 September 2025
GENinCode Plc
("GENinCode" or the "Company")
Comment re: Share price movement
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer , notes the movement in the share price yesterday and again today.
The Company knows no reason for this sudden movement, albeit the board believes the shares remain undervalued. The Company reconfirms its trading and operation position set out in the trading update of 26 August 2025 with FDA De Novo discussions continuing to progress and work ongoing to close out the remaining deficiencies. Collaboration discussions on potential US and EU test distribution are progressing with a major distributer. The Company looks forward to updating the market at its interim results on Tuesday, 30 September 2025.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc |
www.genincode.com or via Walbrook PR |
||
| Matthew Walls, CEO |
|
||
| Paul Foulger, CFO |
|||
|
|
|
||
| Cavendish Capital Markets Limited |
Tel: +44 (0)20 7397 8900 |
||
| Giles Balleny(Corporate Finance) |
|||
| Nigel Birks (Life Sciences Specialist Sales) |
|||
| Harriet Ward (Corporate Broking) |
|||
| Dale Bellis / Michael Johnson (Sales) |
|||
|
|
|
||
| Walbrook PR Limited |
|
||
| Anna Dunphy / Marcus Ulker |
Tel: 020 7933 8780 or [email protected] |
||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.
About Cardiovascular Disease (CVD):
CVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas with the NHS 10 Year Plan identifying CVD as the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.
Early detection and treatment of CVD can help patients live longer, healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year Plan is working towards people knowing and managing risks around their 'ABC' (AF, Blood pressure and Cholesterol).
About Ovarian Cancer (OC) and the ROCA test:
OC occurs when abnormal cells in the ovaries or fallopian tubes grow and multiply out of control. Ovaries are part of the female reproductive system and are responsible for making eggs during a female's reproductive years.
OC affects women and people assigned female at birth. It accounts for 1% of all new cancer cases and the lifetime risk of developing OC is approximately 1 in 78. OC is slightly more common in white populations than in people who are Black, Hispanic or Asian, while people who inherit a BRCA gene mutation are consider high risk of developing the disease. BRCA gene mutations occur in 0.3% of the population but is more common in individuals of Ashkenazi Jewish or Greenlander descent. Preventative surgery (removal of both ovaries and fallopian tubes) is recommended for BRCA carriers.
Diagnosis of OC typically occurs late stage due to the presentation of vague symptoms that are often confused with other more common conditions. As a result, treatment is intense and long-term survival is poor. Despite years of research, experts have struggled to develop an effective OC surveillance test that can detect the disease earlier.
The Risk of Ovarian Cancer Algorithm (ROCA) Test is a globally leading OC surveillance test, proven to detect OC cancer before symptoms present and at an earlier stage. The test is intended for women over 35 with a mutation in the BRCA1 or BRCA2 gene and who wish to defer preventative surgery. The ROCA test has recently received National Institute for Care and Health Excellence (NICE) guideline recommendation for OC surveillance.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.